Načítá se...

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

The epothilone B analog, ixabepilone, demonstrates low susceptibility to drug resistance mechanisms and has demonstrated clinically meaningful efficacy in patients refractory to other chemotherapeutic options. Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Egerton, Nancy
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2010
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2955910/
https://ncbi.nlm.nih.gov/pubmed/20886213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1467-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!